iiinova — where your digital self keeps evolving

Lea Mertens @leamert.bsky.social · 18/03/2026

Excited to share our study on the Efficacy and Safety of Psilocybin in Treatment-Resistant Depression (EPISODE) - now published in @jamapsychiatry.com A negative effect on primary outcome, but evidence for a relevant antidepressant effect of 25 mg psilocybin with psychotherapy in TRD.

041

Reposted by Lea Mertens

Max Wolff @trpwolff.bsky.social · 10/10/2025

New long-read theory paper in Psychological Review: Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies. Full text below ⬇️

2102

Lea Mertens @leamert.bsky.social · 10/10/2025

Goodbye lake como and thank you for a wonderful break after an intense few months of data analysis, paper writing and preparing for my final psychotherapy license exam. Now off to #ECNP2025, where I will be presenting the results of our episode study on Saturday. Meet me at poster PS01-0249!

010

Reposted by Lea Mertens

Max Wolff @trpwolff.bsky.social · 16/06/2025

Reframing Psychedelic Regulation: Tools, not Treatments In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right. The use of anesthetics as treatment tools in surgery is a useful analogy.

Drug Science, Policy and Law
Screenshot of title page and abstract

2248

Reposted by Lea Mertens

josh hardman @josh-hardman.bsky.social · 31/07/2025

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program. Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs. Details: psychedelicalpha.com/news/germany...

psychedelicalpha.com

Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha

Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...

0113

Lea Mertens @leamert.bsky.social · 08/12/2024

Glad to be at #ACNP2024 in Phoenix! On Monday, I will be presenting the results of our episode trial in the session „Psychedelic-assisted Psychotherapy: From preclinical mechanisms to clinical applications“ alongside @fredbarrettphd.bsky.social, @kellietamashiro.bsky.social and Jennifer Mitchell.

083